Schedule 13G ownership disclosure

Celldex Therapeutics Inc

Common Stock · CUSIP: 15117B202

Event date: 2025-08-18

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Bellevue Group AG

    Shares: 3,617,669.00 · Class: 5.4%

  • Bellevue Asset Management AG

    Shares: 3,617,669.00 · Class: 5.4%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-112821
Form type
SCHEDULE 13G
Filer
Bellevue Group AG
CIK
CIK 1674546
Filed
Nov 14, 2025
Reporting period
Aug 18, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub